Histone demethylase RBP2 is critical for breast cancer progression and metastasis

95Citations
Citations of this article
92Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Metastasis is a major clinical challenge for cancer treatment. Emerging evidence suggests that aberrant epigenetic modifications contribute significantly to tumor formation and progression. However, the drivers and roles of such epigenetic changes in tumor metastasis are still poorly understood. Using bioinformatic analysis of human breast cancer gene-expression data sets, we identified histone demethylase RBP2 as a putative mediator of metastatic progression. By using both human breast cancer cells and genetically engineered mice, we demonstrated that RBP2 is critical for breast cancer metastasis to the lung in multiple invivo models. Mechanistically, RBP2 promotes metastasis as a pleiotropic positive regulator of many metastasis genes, including TNC. In addition, RBP2 loss suppresses tumor formation in MMTV-neu transgenic mice. These results suggest that therapeutic targeting of RBP2 is a potential strategy for inhibition of tumor progression and metastasis. © 2014 The Authors.

Cite

CITATION STYLE

APA

Cao, J., Liu, Z., Cheung, W. K. C., Zhao, M., Chen, S. Y., Chan, S. W., … Yan, Q. (2014). Histone demethylase RBP2 is critical for breast cancer progression and metastasis. Cell Reports, 6(5), 868–877. https://doi.org/10.1016/j.celrep.2014.02.004

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free